Cancer- The breaking news on the treatment, cure and diagnosis of cancer

 
 

 
 

  • Search for "cancer news"
  • Argos Therapeutics, Inc. (ARGS) Short Interest Down 21.1% in October

    Argos Therapeutics, Inc. (ARGS) Short Interest Down 21.1% in October
    Argos Therapeutics, Inc. saw a significant decrease in short interest during the month of October. As of October 13th, there was short interest totalling 2,706,234 shares, a decrease of 21.1% from the September 29th total of 3,429,642 shares.
  • ANI Pharmaceuticals (ANIP) vs. United Therapeutics Corporation (UTHR) Head-To-Head Comparison

    ANI Pharmaceuticals (ANIP) vs. United Therapeutics Corporation (UTHR) Head-To-Head Comparison
    ANI Pharmaceuticals and United Therapeutics Corporation are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations. 56.0% of ANI Pharmaceuticals shares are owned by institutional investors.
  • Cowen and Company Reiterates "Buy" Rating for Accuray Incorporated

    Cowen and Company Reiterates "Buy" Rating for Accuray Incorporated
    's stock had its "buy" rating reaffirmed by analysts at Cowen and Company in a research report issued to clients and investors on Friday. They presently have a $9.00 price objective on the medical equipment provider's stock.
  • Head to Head Contrast: OncoSec Medical (ONCS) & Its Rivals

    Head to Head Contrast: OncoSec Medical (ONCS) & Its Rivals
    OncoSec Medical is one of 198 public companies in the "Biotechnology & Medical Research" industry, but how does it weigh in compared to its rivals? We will compare OncoSec Medical to related businesses based on the strength of its analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings. OncoSec Medical has a beta of 2.53, meaning that its stock price is 153% more volatile than the S&P 500.
  • Month of mourning for Zimbabwe Catholics

    Month of mourning for Zimbabwe Catholics
    This period has been a dark month for the Roman Catholic Church in Zimbabwe following the deaths in separate incidences of four ministers - a bishop, two priests and a nun. In a period described by Bulawayo Archbishop Alex Thomas as "a month of tears", the church lost Gweru Diocese Bishop Reverend Xavier Munyongani, Father Peter Nkomazana, Father Martin Schupp and renowned composer of Catholic music Sister Ruvadiki Plaxedes Kamundiya.
  • Biocompare Cancer
  • Tilted Acoustic Tweezers Separate Cells Gently

    Tilted Acoustic Tweezers Separate Cells Gently
    Precise, gentle and efficient cell separation from a device the size of a cell phone may be possible thanks to tilt-angle standing surface acoustic waves, according to a team of engineers.
  • New Biomarker Highly Promising For Predicting Breast Cancer Outcomes

    New Biomarker Highly Promising For Predicting Breast Cancer Outcomes
    A protein named p66ShcA shows promise as a biomarker to identify breast cancers with poor prognoses, according to research published ahead of print in the journal Molecular and Cellular Biology.
  • Finding Keys To Glioblastoma Therapeutic Resistance

    Finding Keys To Glioblastoma Therapeutic Resistance
    Researchers at the University of California, San Diego School of Medicine have found one of the keys to why certain glioblastomas - the primary form of a deadly brain cancer - are resistant to drug therapy. The answer lies not in the DNA sequence of the tumor, but in its epigenetic signature. These findings have been published online as a priority report in the journal Oncotarget.
  • Mimicking Natural Evolution With 'promiscuous Reactions' To Improve The Diversity Of Drugs

    Mimicking Natural Evolution With 'promiscuous Reactions' To Improve The Diversity Of Drugs
    A revolutionary new scientific method developed at the University of Leeds will improve the diversity of 'biologically active molecules', such as antibiotics and anti-cancer agents.
  • Study Suggests Repurposing Anti-Depressant Medication To Target Medulloblastoma

    Study Suggests Repurposing Anti-Depressant Medication To Target Medulloblastoma
    CINCINNATI - An international research team reports in Nature Medicine a novel molecular pathway that causes an aggressive form of medulloblastoma, and suggests repurposing an anti-depressant medication to target the new pathway may help combat one of the most common brain cancers in children.